Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of estrogens and delta-gonadien-21-Ol-3,20-diones for treating insulin dependent and non-insulin dependent diabetes

a technology of estrogen and deltagonadien, which is applied in the direction of biocide, drug composition, metabolic disorder, etc., can solve the problems of diabetes, difficult control of this type of diabetes, and the most susceptible parts of the body,

Inactive Publication Date: 2003-04-29
NOVO NORDISK AS
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although many different organs are affected by these vascular changes, the nerves, eyes and kidneys appear to be the most susceptible.
As such, long-standing diabetes mellitus, even when treated with insulin, is a leading cause of blindness.
Control of this type of diabetes is difficult and requires exogenous insulin administration.
However, even today, a clear picture of the basic biochemical defects of the disease is not known, and diabetes remains a serious health problem.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of estrogens and delta-gonadien-21-Ol-3,20-diones for treating insulin dependent and non-insulin dependent diabetes
  • Use of estrogens and delta-gonadien-21-Ol-3,20-diones for treating insulin dependent and non-insulin dependent diabetes
  • Use of estrogens and delta-gonadien-21-Ol-3,20-diones for treating insulin dependent and non-insulin dependent diabetes

Examples

Experimental program
Comparison scheme
Effect test

examples

Conjugated estrogens may be obtained following the process described in U.S. Pat. No. 2,720,483 or U.S. Pat. No. 2,565,115, which are incorporated herein by reference.

The compound having the formula II ##STR11##

may be prepared as described in U.S. Pat. No. 4,273,771. The compound of formula II is called trimegestone.

An example of a tablet contains a conjugated estrogen (0,6 mg) and a compound of formula II (2,4 mg) formulated with pharmaceutically acceptable carriers to provide a medicament for oral administration according to conventional methods. The formulation further include the following diluents, fillers, emulsifiers, preservatives, buffers and / or excipients, that is calcium phosphate tribasic, calcium sulfate, canauba wax, cellulose, glyceryl monooleate, lactose, magnesium stearate, methylcellulose, pharmaceutical glaze, polyethylen glycol, sucrose, povidone, titanium dioxide and red ferric oxide. One skilled in this art may formulate the tablet composition in an appropriate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
concentrationsaaaaaaaaaa
pharmaceutical compositionsaaaaaaaaaa
Login to View More

Abstract

Analysis of full-blood glucose, serum insulin, serum triglycerides and total serum cholesterol were performed. Glucose levels in blood samples from the oral glucose tolerance test were used for calculation of the incremental Area Under the Curve (AUC0-120 min-baseline). All data are expressed as percentage change of vehicle treated animals (cf. FIGS. 1 and 2).

Description

FIELD OF THIS INVENTIONThe present invention relates to the use of a combination of estrogens or SERMs with delta-gonadien-21-ol-3,20-diones for treating diabetes, particularly type II diabetes. The present invention also embraces pharmaceutical compositions and kits comprising these compounds and methods of using the compounds and their pharmaceutical compositions.BACKGROUND OF THIS INVENTIONDiabetes mellitus is a systemic disease characterized by disorders in the actions of insulin and other regulatory hormones in the metabolism of carbohydrates, fats and proteins, and in the structure and function of blood vessels. The primary symptom of diabetes is hyperglycemia, often accompanied by glucosuria, the presence in urine of large amounts of glucose, and polyuria, the excretion of large volumes of urine. Additional symptoms arise in chronic or long standing diabetes. These symptoms include degeneration of the walls of blood vessels. Although many different organs are affected by thes...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K31/575A61P3/10A61P43/00
CPCA61K31/575A61K31/565A61K2300/00A61P3/10A61P43/00
Inventor WASSERMANN, KARSTEN
Owner NOVO NORDISK AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com